Home > Publications database > Phenotypic Discovery of Triazolo[1,5- c ]quinazolines as a First-In-Class Bone Morphogenetic Protein Amplifier Chemotype > print

001     619713
005     20250929155356.0
024 7 _ |a 10.1021/acs.jmedchem.2c01199
|2 doi
024 7 _ |a 0095-9065
|2 ISSN
024 7 _ |a 0022-2623
|2 ISSN
024 7 _ |a 1520-4804
|2 ISSN
024 7 _ |a 1943-2992
|2 ISSN
024 7 _ |a altmetric:138196918
|2 altmetric
024 7 _ |a pmid:36346705
|2 pmid
024 7 _ |a WOS:000886229700001
|2 WOS
024 7 _ |a openalex:W4308524286
|2 openalex
037 _ _ |a PUBDB-2024-07852
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wesseler, Fabian
|b 0
245 _ _ |a Phenotypic Discovery of Triazolo[1,5- c ]quinazolines as a First-In-Class Bone Morphogenetic Protein Amplifier Chemotype
260 _ _ |a Washington, DC
|c 2022
|b ACS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1734528730_2751524
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Phenotypic drug discovery (PDD) continues to fuel the research and development pipelines with first-in-class therapeutic modalities, but success rates critically depend on the quality of the underlying model system. Here, we employed a stem cell-based approach for the target-agnostic, yet pathway-centric discovery of small-molecule cytokine signaling activators to act as morphogens during development and regeneration. Unbiased screening identified triazolo[1,5-c]quinazolines as a new-in-class in vitro and in vivo active amplifier of the bone morphogenetic protein (BMP) pathway. Cellular BMP outputs were stimulated via enhanced and sustained availability of BMP-Smad proteins, strictly dependent on a minimal BMP input. Holistic target deconvolution unveiled a unique mechanism of dual targeting of casein kinase 1 and phosphatidyl inositol 3-kinase isoforms as key effectors for efficient amplification of osteogenic BMP signaling. This work underscores the asset of PDD to discover unrecognized polypharmacology signatures, in this case significantly expanding the chemical and druggable space of BMP modulators.
536 _ _ |a 6G3 - PETRA III (DESY) (POF4-6G3)
|0 G:(DE-HGF)POF4-6G3
|c POF4-6G3
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: bib-pubdb1.desy.de
693 _ _ |a PETRA III
|f PETRA Beamline P13
|1 EXP:(DE-H253)PETRAIII-20150101
|0 EXP:(DE-H253)P-P13-20150101
|6 EXP:(DE-H253)P-P13-20150101
|x 0
700 1 _ |a Lohmann, Stefan
|b 1
700 1 _ |a Riege, Daniel
|b 2
700 1 _ |a Halver, Jonas
|b 3
700 1 _ |a Roth, Aileen
|b 4
700 1 _ |a Pichlo, Christian
|b 5
700 1 _ |a Weber, Sabrina
|b 6
700 1 _ |a Takamiya, Masanari
|b 7
700 1 _ |a Müller, Eva
|b 8
700 1 _ |a Ketzel, Jana
|b 9
700 1 _ |a Flegel, Jana
|b 10
700 1 _ |a Gihring, Adrian
|b 11
700 1 _ |a Rastegar, Sepand
|b 12
700 1 _ |a Bertrand, Jessica
|b 13
700 1 _ |a Baumann, Ulrich
|b 14
700 1 _ |a Knippschild, Uwe
|b 15
700 1 _ |a Peifer, Christian
|0 0000-0003-1532-7826
|b 16
700 1 _ |a Sievers, Sonja
|b 17
700 1 _ |a Waldmann, Herbert
|0 0000-0002-9606-7247
|b 18
700 1 _ |a Schade, Dennis
|0 0000-0002-5515-1821
|b 19
|e Corresponding author
773 _ _ |a 10.1021/acs.jmedchem.2c01199
|g Vol. 65, no. 22, p. 15263 - 15281
|0 PERI:(DE-600)1491411-6
|n 22
|p 15263 - 15281
|t Journal of medicinal chemistry
|v 65
|y 2022
|x 0095-9065
856 4 _ |u https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c01199
856 4 _ |u https://bib-pubdb1.desy.de/record/619713/files/Phenotypic%20Discovery%20of%20Triazolo%201%2C5-%20c%20quinazolines%20as%20a%20First-In-Class%20Bone%20Morphogenetic%20Protein%20Amplifier%20Chemotype.pdf
|y Restricted
856 4 _ |u https://bib-pubdb1.desy.de/record/619713/files/Phenotypic%20Discovery%20of%20Triazolo%201%2C5-%20c%20quinazolines%20as%20a%20First-In-Class%20Bone%20Morphogenetic%20Protein%20Amplifier%20Chemotype.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:bib-pubdb1.desy.de:619713
|p VDB
913 1 _ |a DE-HGF
|b Forschungsbereich Materie
|l Großgeräte: Materie
|1 G:(DE-HGF)POF4-6G0
|0 G:(DE-HGF)POF4-6G3
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-600
|4 G:(DE-HGF)POF
|v PETRA III (DESY)
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1200
|2 StatID
|b Chemical Reactions
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1210
|2 StatID
|b Index Chemicus
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J MED CHEM : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J MED CHEM : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-H253)EMBL-User-20120814
|k EMBL-User
|l EMBL-User
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-H253)EMBL-User-20120814
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21